Evoke Pharma (EVOK) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Evoke Pharma Reports First Quarter 2016 Results
May 11, 2016 4:05 PM EDTSOLANA BEACH, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the first quarter ended March 31, 2016.
Dave Gonyer, R.Ph., President and CEO, stated, The start of 2016 has been a very significant time for Evoke as we are now one step closer to the potential commercialization of EVK-001 with the completion of enrollment in our pivotal Phase 3 trial. We look forward to providing study results early in the third quarter of this... More
